Teewinot Life Sciences secures first US patent covering an apparatus for the biosynthetic production of authentic THCA, CBDA And CBCA cannabinoids

The apparatus facilitates the manufacture of authentic cannabinoids that are purer in form and more cost effectively produced than what is currently available in the marketplace.

Teewinot's executive vice president and co-inventor of the '510 patent, Dr Richard Peet, stated: "Teewinot has a rapidly expanding patent portfolio covering processes for the manufacture of cannabinoids, cannabinoid prodrugs and cannabinoid analogs, as well as novel cannabinoids and treatment therapies."

Jeffrey M. Korentur, Teewinot's CEO stated: "We are proud to add to the technological foundation that will allow this new class of medicines reach their full potential. Our processes, equipment, and expertise will, for the first time, allow for the inexpensive and rapid production of pure cannabinoids and cannabinoid-related compounds for the benefit of patient populations around the world."

With federally licensed laboratories in Canada, an Irish subsidiary, and global headquarters in Tampa, Florida, Teewinot is ready to manufacturer cannabinoids, cannabinoid prodrugs, and cannabinoid analogs worldwide.